Treating Pulmonary Hypertension (PAH) with a known T2DM pill: Acarbose inhibits pulmonary hypertension via induction of PDLIM5, 13/February/2015, 22.10

Treating Pulmonary Hypertension (PAH) with a known T2DM pill: Acarbose inhibits pulmonary hypertension via induction of PDLIM5, 13/February/2015, 22.10

Treating Pulmonary Hypertension (PAH) with a known T2DM pill: Acarbose inhibits pulmonary hypertension via induction of PDLIM5, 13/February/2015, 22.10 150 150 Dr Boomi's Genom-2-Discovery Center

Idea Proposed/Formulated byDr L Boominathan Ph.D.

Web: http://genomediscovery.org

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Significance: This study suggests, for the first time, that Acarbose may increase the expression of PDLIM5. Thereby, it may inhibit pulmonary hypertension. Together, pharmacological formulations encompassing “Acarbose or its analogues may be used to treat pulmonary arterial hypertension (PAH).

Amount: $ 500*

Undisclosed information: How Acarbose increases the expression of PDLIM5

To citeBoominathan, Treating Pulmonary Hypertension (PAH) with a known T2DM pill: Acarbose inhibits pulmonary hypertension via induction of PDLIM5, 13/February/2015,  22.10,  Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org